NCT00301756: Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors |
|
|
| Completed | 2 | 32 | Canada | Belinostat, Beleodaq, PXD 101, PXD101, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Ovarian Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Ovarian Cancer | 08/09 | 12/12 | | |
NCT00421889 / 2005-002338-36: A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment |
|
|
| Completed | 1/2 | 80 | US, Europe | belinostat, PXD101, Paclitaxel, Carboplatin | Onxeo | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer | 02/09 | 02/09 | | |
